Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 6 - Right-of-use Assets, Operating Leases

Note 6 - Right-of-use Assets, Operating Leases

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Right-of-use Assets Disclosure [Text Block]

6.	Right-of-use assets, operating leases:

		Year ended December 31, 2021				Year ended December 31, 2020

Right-of-use assets, beginning of year		$	1,848			$	1,837
Additions to right-of-use assets			12				11
Right-of-use assets, end of year			1,860				1,848
Accumulated amortization			(1,395	)			(923	)
Right-of use assets, NBV		$	465			$	925